Identification and characterisation of MCLA-158 as an anti-EGFRxLGR5 bispecific antibody that potently inhibits patient-derived CRC organoid growth

Rob C. Roovers1, Bram Herpers2, Mark James3, Berina Eppink1, Carme Cortina3, David Maussang-Detaille1, Ingrid Kolfschoten1, Sylvia F. Boy4, Marc van de Wetering4, Wim de Lau5, Robert Doornbos1, Carina Clements1, Abdul Basmeleh1, Willem Bartelink1, Vanessa Zondag van de Zande1, Kuan Yan2, Lucia Salinaro2, Lex Bakker1, John de Kruif1, Hans Clevers5, Robert Vries4, Eduard Batlle3, Leo Price2 and Mark Throsby1.1Merus NV, Utrecht, Netherlands; 2OcellO BV, Leiden, Netherlands; 3IRB Barcelona, Spain; 4HUB, Utrecht, Netherlands; 5The Hubrecht Institute, Utrecht, Netherlands.

Poster presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting, Washington, DC, USA.